Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:amphotericin_B
|
| gptkbp:activities |
disrupts fungal cell membrane
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:1997
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Am_Bisome
|
| gptkbp:clinical_trial |
Phase III
serious fungal infections |
| gptkbp:contains |
liposomal amphotericin B
|
| gptkbp:contraindication |
hypersensitivity to amphotericin B
other amphotericin B formulations |
| gptkbp:developed_by |
gptkb:Gilead_Sciences
|
| gptkbp:dosage_form |
gptkb:software_framework
|
| gptkbp:formulation |
liposomal
|
| https://www.w3.org/2000/01/rdf-schema#label |
Am Bisome
|
| gptkbp:indication |
aspergillosis
leishmaniasis cryptococcal meningitis |
| gptkbp:ingredients |
gptkb:amphotericin_B
|
| gptkbp:interacts_with |
corticosteroids
nephrotoxic agents |
| gptkbp:invention |
patented
|
| gptkbp:is_available_on |
generic version
|
| gptkbp:is_monitored_by |
electrolytes
renal function infusion reactions |
| gptkbp:is_used_for |
treating fungal infections
|
| gptkbp:issues |
certain IV solutions
|
| gptkbp:manager |
intravenous
|
| gptkbp:marketed_as |
multiple countries
Amphotericin B liposome |
| gptkbp:packaging |
vial
|
| gptkbp:pharmacokinetics |
long half-life
fungicidal activity |
| gptkbp:price |
high
|
| gptkbp:provides_information_on |
recommended for immunocompromised patients
|
| gptkbp:requires |
gptkb:stock_market_index
|
| gptkbp:research_focus |
reducing side effects
enhancing efficacy improving delivery systems |
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
gptkb:fandom
headache nausea fever chills hypokalemia renal toxicity thrombophlebitis |
| gptkbp:storage |
room temperature
|